Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase.
This report presents an accurate portrayal of all the factors that influence the global postmenopausal vaginal atrophy treatment and drug market. It studies the relevant factors that surround this market with the intention of providing its readers influential guidance. The report considers all the factors that have influenced the global postmenopausal vaginal atrophy treatment and drug market so far and predicts that ones that will influence it in the near future. To establish the future prospects of this market, highly competent methodologies have been implemented. Through these procedures, it is deduced where the global postmenopausal vaginal atrophy treatment and drug market is headed.
The global postmenopausal vaginal atrophy treatment and drug market is segmented based on the vaginal atrophy epidemiology in relation to different regions, age, prevalence, and severity.
The report thus covers all grounds of the global postmenopausal vaginal atrophy treatment and drug market, including drivers, restraints, and market trends. The analysis also accounts for the most recent drugs and technologies that have been devised in this market. The report employs the Porter’s Five Forces model analysis, along with a SWOT analysis of the major market players. There is a detailed explanation of each macro and micro factor that is essential for all the players in the market, whether existing ones or new entrants.
Overview of the Global Postmenopausal Vaginal Atrophy Treatment and Drug Market
Most of the recent developments in the global postmenopausal vaginal atrophy treatment and drug market have been highly positive. The growth of this market is attributed to the growing percentage of the geriatric demographic, cultural changes in the perception of sexuality and its medical complications, and the launch of major non-estrogen-based drugs. These drugs include Osphena and Vaginorm. Another factor promoting the growth of the global postmenopausal vaginal atrophy treatment and drug market is the improvement of the Affordable Care Act to accommodate this medical condition.
On the other hand, the market is being restrained by the influx of a large number of generic drugs that are priced much lower than their patented competitors. This has happened due to the patent expiration of several major drugs and through multiple licensing agreements. Some of the major branded drugs for vaginal atrophy in the market today are Premarin, Estrace, Estring, Vagifem, and Colpotrophine.
Companies mentioned in the research report
The key players in the global postmenopausal vaginal atrophy treatment and drug market are Bristol Myers, Novartis, Pfizer, Merck, and Mylan.
Major regions analyzed under this research report are:
- North America
- Asia Pacific
- Rest of the World
This report gives you access to decisive data such as:
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for the coming years
Key highlights of this report
- Overview of key market forces propelling and restraining market growth
- Up-to-date analyses of market trends and technological improvements
- Pin-point analyses of market competition dynamics to offer you a competitive edge
- An analysis of strategies of major competitors
- An array of graphics and SWOT analysis of major industry segments
- Detailed analyses of industry trends
- A well-defined technological growth map with an impact-analysis
- Offers a clear understanding of the competitive landscape and key product segments